LFB presents its strategic transformation

Priority on industrial activity to support market growth
An industrial investment plan to build a new plant in Arras (France) has been implemented involving an initial €62 million tranche. This investment will enable LFB to step up its production capacity, supporting its international growth and increasing medicines available to patients. LFB expects to create up to 250 jobs by 2024. In addition, LFB is actively working to address ANSM’s injunctions at its industrial site. In this context, 60 new hires in production and quality are planned for 2019.

Refocusing on core business activities, plasma derived or recombinant therapeutic proteins
LFB has taken a strategic decision to refocus on its core business – production and provision of its 15 plasma or recombinant protein derived products used in immunology, haematology and emergency medicine.
Four strategic development projects have been selected for their strong growth potential in LFB’s core business:

• Recombinant activated Factor VII: Filing of a marketing authorisation application for this product, which treats patients with congenital haemophilia A or B with inhibitors, in the USA in 2019,
• Immunoglobulin G10% IV liquid aim to file a US marketing application for this drug in the treatment of patients with primary immunodeficiency disease,
• Fibrinogen is used for perioperative prevention and treatment of bleedings in patients with congenital fibrinogen deficiency. Development of a new indication for use in patients with fibrinogen deficiency related to severe post-traumatic haemorrhage.
• Willebrand factor is used for treating and preventing surgical bleeds in Von Willebrand disease patients, when desmopressin either can’t be used or is ineffective. Development of a new indication for use in patients with bleedings related to a left ventricular assist device for cardiac insufficiency (acquired von Willebrand syndrome).

Consolidation of LFB’s leadership in France and targeted international growth
Consolidating LFB’s leadership in France will depend on:

• Gaining back market share and customers,
• Maximizing potential of existing medicinal products portfolio,
• Launching a new medicine, introducing new indications and new dosage on some of our medicines.

In particular, this goal will be dependent on maintaining a strong commercial presence, focusing on key products and customers.
Outside France, LFB has decided on a targeted strategy, focusing on specific markets with key drugs:

• Targeting its business activities towards markets with key advantages such as USA, Germany, UK, Spain, Italy, Belgium, Turkey and Mexico.
• Focusing development on key products which will benefit from this targeted strategy.

Implementing a new organisation aligned with the refocused business portfolio, including a specific voluntary departure plan (RCC)
The strategic transformation project unveiled today is the result of a strategic review launched several months ago. Some content of this project is bound to impact some LFB staff, particularly in France.
LFB takes its social responsibilities extremely seriously. This was clearly expressed to the staff representatives gathered for the opening meeting of the consultation process which aims to reach a majority agreement on a specific voluntary departure plan (RCC) for approximately 120 volunteers, and where the new organisation was presented. LFB intends to implement a dedicated and socially responsible support plan for staff volunteers for them to successfully complete their professional project.